4-(二氟甲氧基)-2-甲基-1-硝基苯 | 795303-16-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(二氟甲氧基)-2-甲基-1-硝基苯
• 英文名称: 4-(difluoromethoxy)-2-methyl-1-nitrobenzene
• CAS: 795303-16-1
• 化学式: C₈H₇F₂NO₃
• 分子量: 203.145
• InChiKey: ZMQMGYRUUZPIOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2909309090
• 储存条件：
  应将产品存放在室温、避光且充满惰性气体的环境中。

反应信息

• 作为反应物：
  描述：

  4-(二氟甲氧基)-2-甲基-1-硝基苯 在 iron(III) chloride hexahydrate 、 甲烷 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 5-(difluoromethoxy)-1H-indole
  参考文献：
  名称：

  Convenient modification of the Leimgruber-Batcho indole synthesis: reduction of 2-nitro-β-pyrrolidinostyrenes by the FeCl3–activated carbon–N2H4∙H2O system

  摘要：

  A new catalytic system containing ferric chloride, activated carbon, and hydrazine has been proposed for the reductive cyclization of beta-dialkylamino-2-nitrostyrenes to give the corresponding indoles (Leimgruber-Batcho synthesis). Various substituted indoles may be obtained in high yield under these conditions.

  DOI：

  10.1007/s10593-011-0776-2
• 作为产物：
  描述：

  氟里昂-22 、 4-硝基间甲苯酚 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.5h， 生成 4-(二氟甲氧基)-2-甲基-1-硝基苯
  参考文献：
  名称：

  [EN] POLYCYCLIC DIAZODIOXIDE-BASED BCL-2 PROTEIN ANTAGONIST
  [FR] ANTAGONISTE DE PROTEINE BCL-2 A BASE DE DIAZODIOXYDE POLYCYCLIQUE

  摘要：

  提供化学式为8的化合物：A和B分别独立地选自于-NO-，-SO-和-NR9-的群组。C是单键或双键。D选自单键的群组，E选自单键，双键，-NR9-，-0-，-S-，-SO-和-S02-的群组；m和n各自独立地是从0到6的整数。R1到R9适当选择以优化理化和/或生物性质，如亲脂性，生物利用度，药代动力学，Bcl-2和Bcl-XL活性，代谢等。R1和R2，R2和R3，R3和R4，R5和R6，R6和R7或R7和R8可以选择性地结合在一起形成芳香或杂环，包括但不限于萘基，喹啉基，异喹啉基，苯并咪唑基，苯并噁唑基，苯并噻唑基等。这些化合物可用于肿瘤治疗应用。这些化合物通过Bcl-2家族蛋白介导诱导肿瘤细胞凋亡。

  公开号：

  WO2004099162A1

文献信息

• Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
  申请人：——

  公开号：US20040248877A1

  公开（公告）日：2004-12-09

  Compounds of Formula 8 are provided: 1 A and B are each independently selected from the group consisting of —NO—, —SO—, and —NR 9 —. C is a single bond or a double bond. D is selected from the group consisting of single bond, 2 E is selected from the group consisting of single bond, double bond, —NR 9 —, —O—, —S—, —SO—, and —SO 2 —; and m and n are each independently an integer from 0 to 6. R 1 to R 9 are appropriately selected to optimize physicochemical and/or biological properties such as lipophilicity, bioavailability, pharmacokinetics, Bcl-2 and Bcl-X L activities, metabolism, and the like. R 1 and R 2 , R 2 and R 3 , R 3 and R 4 , R 5 and R 6 , R 6 and R 7 , or R 7 and R 8 may optionally be joined together to form an aromatic or heteroaromatic ring, including, but not limited to, naphthyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl and the like. The compounds are useful for tumor therapeutic applications. These compounds induce apoptosis in tumor cells mediated through Bcl-2 family of proteins.

  提供了化学式8的化合物：1A和B各自独立地选择自—NO—，—SO—和—NR9—的组。C是单键或双键。D从单键的组中选择，2E从单键，双键，—NR9—，—O—，—S—，—SO—和—SO2—的组中选择；m和n分别独立地为0到6的整数。R1到R9适当选择以优化物理化学和/或生物学特性，如亲脂性，生物利用度，药代动力学，Bcl-2和Bcl-XL活性，代谢等。R1和R2，R2和R3，R3和R4，R5和R6，R6和R7或R7和R8可以选择性地结合形成芳香或杂环，包括但不限于萘基，喹啉基，异喹啉基，苯并咪唑基，苯并噁唑基，苯并噻唑基等。这些化合物适用于肿瘤治疗应用。这些化合物通过Bcl-2蛋白家族介导诱导肿瘤细胞凋亡。
• Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site
  作者：S. David Kimball、David M. Floyd、Jagabandhu Das、John T. Hunt、John Krapcho、George Rovnyak、Keith J. Duff、Ving G. Lee、Robert V. Moquin

  DOI：10.1021/jm00082a020

  日期：1992.2

  We have synthesized a series of benzazepinones (2) in order to determine the structure-activity relationships (SAR) for calcium channel blockers related to diltiazem. A prerequisite for calcium channel blocking activity in vitro and in vivo is the presence of two pharmacophores: a 4'-aryl methyl ether and a basic substituent appended to N1 with a pK(a) in the physiological range. When these constraints are satisfied, a wide variety of substitution is tolerated at C6, C7, and C3. The presence of an electron-withdrawing group at C6 appears to enhance potency in vitro and in vivo. For such benzazepinones, activity is primarily dependent upon lipophilicity, as measured by log P. We believe these compounds must partition into the cell membrane in order to access their receptor. The quaternary methiodide 15k was used to demonstrate that the binding site for benzazepinones is on the intracellular face of the membrane. This work represents the first comprehensive SAR of diltiazem-like calcium channel blockers.
• Covalent PPARG inverse-agonists
  申请人：Bayer Aktiengesellschaft

  公开号：US20240150277A1

  公开（公告）日：2024-05-09

  The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.